Navigation Links
At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
Date:10/22/2013

EXTON, Pa., Oct. 22, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that at one month post-launch, approximately one-quarter of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF-inhibitor Tafinlar for malignant melanoma, compared with 15 percent who report having prescribed GlaxoSmithKline's MEK inhibitor, Mekinist.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

According to the first wave of the LaunchTrends® Tafinlar/Mekinist report series, the inability to differentiate between Tafinlar and Mekinist from Roche/Genentech/Daiichi Sankyo's first-to-market BRAF-inhibitor Zelboraf is the greatest constrainer of medical oncologists' prescribing of these new market entrants. While use of Tafinlar and Mekinist in combination is not FDA-approved, surveyed oncologists believe combination therapy may represent the ultimate strategy for treating BRAF-mutated unresectable/metastatic malignant melanoma and provide the optimal platform for differentiation from Zelboraf.

The report also finds that approximately half of all surveyed U.S. medical oncologists are highly willing to prescribe Tafinlar and Mekinist as monotherapies, with more than three-quarters of nonprescribers reporting that they intend to prescribe Tafinlar and Mekinist within the next six months. For first-line BRAF-mutated unresectable/metastatic malignant melanoma, the highest percentage of surveyed U.S. medical oncologists indicated that they would prescribe Tafinlar in patients with brain metastases, whereas the highest percentage of surveyed U.S. medical oncologists reported they would be most likely to prescribe Mekinist in patients harboring the BRAF V600K mutation.

"Interestingly, almost 50 percent of surveyed U.S. medical oncologists indicated they would prescribe Tafinlar or Mekinist in BRAF-mutated unresectable/metastatic malignant melanoma in patients who had progressed on a first-line of Zelboraf," said Decision Resources Group Senior Business Insights Analyst Karen Pomeranz, M.Sc., Ph.D. "This use of Tafinlar and Mekinist arises despite only provisional evidence to suggest Tafinlar exhibits efficacy following treatment with Zelboraf. Moreover, Mekinist is specifically not indicated for treatment of patients who have progressed on prior BRAF-inhibitor therapy."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

 


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hologic to Mark Start of Breast Cancer Awareness Month with NASDAQ Opening Bell Ceremony
2. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
3. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
4. Users of PediaVisions Spot Vision Screener Honor Childrens Eye Health and Safety Month with Back-to-School Screenings
5. International Isotopes Inc. Announces Second Quarter and Six Months 2013 Financial Results
6. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
7. For Multiple Sclerosis Treatment, Prescriber Base for Genzymes Aubagio Among U.S. Neurologists Has Increased Significantly at Six Months Post-launch, Compared to One and Three Months Post-launch
8. InspireMDs MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
9. ALK Partners with AAFA to Launch New Online Resource for Allergic Patients During Allergy & Asthma Awareness Month
10. Pro-Dex, Inc. Announces Fiscal Third Quarter And Nine-Month Results
11. Addressing Hearing Loss Proves Win-Win for Both Employer and Employee, BHI Advises During National Employee Wellness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Newborns are highly vulnerable to infections ... their young immune systems typically mount weak antibody ... achieving strong vaccine responses in newborn animals, including ... trials — by adding compounds known as adjuvants ... papers, they also describe improved adjuvant formulations that ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
(Date:3/23/2017)... , March 23, 2017 ... Composite ended the trading session at 5,821.64, up ... lower, to finish at 20,661.30; and the S&P ... were broad based as six out of nine ... Stock-Callers.com has initiated reports coverage on the following ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... The physicians of ... in the greater Houston Area. The new location is located at 2255 E. Mossy ... in Springwoods Village. This newest location will provide patients living in the north Houston ...
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... Gruene Road in Building 2. The clinic is the group’s second in New Braunfels ... opening the company’s second New Braunfels location brings things full circle for the group, ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... to $11 trillion dollars by the year 2025. McKinsey expects the IoT to have ...
(Date:3/23/2017)... ... ... are unaware of the dangers that infectious bacteria play in mouth disease, while 1 out ... that dentists recommend. The ramifications of improper oral upkeep go far beyond bad breath and ... hours of work each year due to dental issues. That is why Mediaplanet is proud ...
(Date:3/23/2017)... ... ... March is National Kidney Month – the perfect time to pause and ... health. Every day, two kidneys filter about 120 to 150 quarts of blood. Put ... waste, regulating fluid levels and blood pressure, supporting bone health and promoting red blood ...
Breaking Medicine News(10 mins):